New Delhi, March 12 -- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca's Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy for the treatment of non-small cell lung cancer (NSCLC). This recommendation is based on the positive results from the Phase III AEGEAN trial, which demonstrated significant improvements in patient outcomes.

AEGEAN Trial Findings The AEGEAN trial evaluated the efficacy of Imfinzi combined with neoadjuvant chemotherapy, followed by adjuvant Imfinzi monotherapy, in patients with NSCLC. The study met its primary endpoints, showing a 32% reduction in the risk of disease recurrence, progression, or death compared to c...